Fernando J. Bianco

Fernando J. Bianco

Auto-generated profile, based on publicly available information

Fernando J. Bianco

Urological Research Network Corp ., Miami Lakes, FL 33016

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in European Urology
Verified
Journal Article
Closed access
FBFernando J. Bianco
Fernando J. Bianco

17 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EFEsaú Fernández-Pascual
Esaú Fernández-Pascual
Celeste ManfrediCeleste Manfredi
Celeste Manfredi
CMCristina Martín
Cristina Martín
CMClaudio Martínez-Ballesteros
Claudio Martínez-Ballesteros
CBCarlos Balmori
Carlos Balmori
JMJuan Ignacio Martínez-Salamanca
Juan Ignacio Martínez-Salamanca
Targeted therapy (TT) for prostate cancer (PCa) aims to ablate the malignant lesion with an adequate margin of safety in order to obtain similar oncological outcomes, but with less toxicity than radical treatments. The main aim of this study was to evaluate the recurrence rate (RR) in patients with primary localized PCa undergoing mpMRI/US fusion targeted cryotherapy (FTC). A secondary objective was to evaluate prostate-specific antigen (PSA) as a predictor of recurrences. We designed a prospective single-center single-cohort study. Patients with primary localized PCa, mono or multifocal lesions, PSA ≤ 15 ng/mL, and a Gleason score (GS) ≤ 4 + 3 undergoing FTC were enrolled. RR was chosen as the primary outcome. Recurrence was defined as the presence of clinically significant prostate cancer in the treated areas. PSA values measured at different times were tested as predictors of recurrence. Continuous variables were assessed with the Bayesian t-test and categorical assessments with the chix-squared test. Univariate and logistic regression assessment were used for predictions. A total of 75 cases were included in the study. Ten subjects developed a recurrence (RR: 15.2%), while fifty-six (84.8%) patients showed a recurrence-free status. A %PSA drop of 31.5% during the first 12 months after treatment predicted a recurrence with a sensitivity of 53.8% and a specificity of 79.2%. A PSA drop of 55.3% 12 months after treatment predicted a recurrence with a sensitivity of 91.7% and a specificity of 51.9%. FTC for primary localized PCa seems to be associated with a low but not negligible percentage of recurrences. Serum PSA levels may have a role indicating RR.

14 May 2002 in Cancer
Verified
Journal Article
Open access
PDF file
MBMousumi Banerjee
Mousumi Banerjee
IPIsaac J. Powell
Isaac J. Powell
JGJulie George
Julie George
DBDebjit Biswas
Debjit Biswas
FBFernando Bianco
Fernando Bianco
RSRichard K. Severson
Richard K. Severson
BACKGROUND It is well established that African‐American men (AAM) have a worse mortality from prostate carcinoma (PC) than White men (WM). Outcome data for men treated with radical prostatectomy for clinically localized PC demonstrate more advanced tumors and higher biochemical recurrence rates among AAM compared with WM. The objective of the current study was to characterize the pattern of prostate specific antigen (PSA) progression by race in patients experiencing disease recurrence after undergoing radical prostatectomy. Racial differences in the pattern of rising PSA would warrant different intervention strategies for reducing the disproportionality in survival outcomes between the two racial groups. METHODS Between 1991–1996, 1080 consecutive men underwent radical prostatectomy for clinically localized PC at Wayne State University‐affiliated Harper Hospital. Two hundred forty‐one patients developed a biochemical recurrence on or before January, 1, 1999. The median follow‐up was 39 months. Longitudinal PSA profiles of 77 men who met the study inclusion criteria were analyzed. Average relative velocities of PSA were compared between AAM and WM. Linear mixed effects regression was used to test the hypothesis that, after adjusting for age, preoperative PSA, stage and grade of disease, PSA levels increase at a faster rate in AAM compared with WM. RESULTS The mean average relative velocity for AAM and WM experiencing a disease recurrence was 0.25 ng/mL and 0.11 ng/mL per month, respectively (P = 0.21). The relative rate of PSA increase in patients who developed a disease recurrence after radical prostatectomy was 18.9% per month for AAM and 16.3% per month for WM (P = 0.73). CONCLUSIONS AAM and WM appear to have similar rates of PSA progression after undergoing radical prostatectomy. Cancer 2002;94:2577–83. © 2002 American Cancer Society. DOI 10.1002/cncr.10535

1 February 2024 in JU Open Plus
Verified
Journal Article
Open access
FBFernando J. Jr. Bianco
Fernando J. Jr. Bianco
ELEusebio Luna
Eusebio Luna
ALAlberto Lopez-Prieto
Alberto Lopez-Prieto
PGPedro González
Pedro González
EGEdward L. Gheiler
Edward L. Gheiler
GMGiuseppe Maiolino
Giuseppe Maiolino
Purpose: To evaluate the safety and tolerability profile of transperineal laser ablation (TPLA) for patients with benign prostatic hyperplasia in an office setting under sedative-free anesthesia, including the functional outcome results at 24 months. Materials and Methods: This is a prospective, single-center, dose range confirmatory trial involving 20 male patients. TPLA was performed by urologists in an office setting, using nonsedative local anesthesia. Self-administered nitrous oxide/oxygen dissociating gas was optional. Tolerability was assessed using a visual analog scale. Safety was evaluated by recording Grade 3 or worse adverse events within 30 days after the procedure. International Prostate Symptom Score, Sexual Health Inventory for Men, ejaculation function, and uroflowmetry parameters were assessed at 6, 12, and 24 months. Results: All 20 procedures were performed as intended without request of cessation from any patient, who tolerated them very well, recording a median pain score of 2 (range 1-4). It is important to note that there was a rapid escalation of dose, and the last 18 consecutive patients were initiated at the maximal energy dose of 7 watts. No hospital transfers were recorded, and no urgent hospital admissions within 30 days post-procedure occurred. There was 1 Grade 3 complication registered during the 24-month study interval. We observed a statistically significant and sustained reduction in the median International Prostate Symptom Score at 6 months (6, 3-8), 12 months (3, 5-2), and 24 months (3, 2-4) when compared with baseline values (14, 12-17). Uroflowmetry parameters showed a similar trend. The median Sexual Health Inventory for Men values did not change significantly, and only approximately 10% of patients reported absence of anterograde ejaculation at 12 and 24 months. Conclusions: TPLA for benign prostatic hyperplasia is a safe and well-tolerated office-based procedure, with durable benefits on functional outcomes over 2 years of follow-up. Further studies are required to confirm these results. NCT: NCT04760483.

1 January 2024 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
LSLARA RODRIGUEZ SANCHEZ
LARA RODRIGUEZ SANCHEZ
MEMark Emberton
Mark Emberton
Theo M. de ReijkeTheo M. de Reijke
Theo M. de Reijke
PSPhillip Stricker
Phillip Stricker
BLBernardino Miñana López
Bernardino Miñana López
RSRafael Sanchez-Salas
Rafael Sanchez-Salas
Rodríguez-Sánchez L, et al. World J Mens Health. 2023 Oct;41:e80. https://doi.org/10.5534/wjmh.230160

1 March 2025 in Journal of Endourology
Verified
Journal Article
Closed access
GMGiuseppe Maiolino
Giuseppe Maiolino
ALAlberto Lopez-Prieto
Alberto Lopez-Prieto
GEGloria Egui-Benatuil
Gloria Egui-Benatuil
AKAriel M. Kaufman
Ariel M. Kaufman
EGEdward L. Gheiler
Edward L. Gheiler
FBFernando J. Bianco
Fernando J. Bianco
Introduction: Focal therapy (FT) is an emerging option for intermediate-risk prostate cancer (IR-PCa). Transperineal MRI fusion laser ablation of PCa (TPFLA) is a novel FT technique with limited data reported. We conducted a phase I clinical trial evaluating the safety, feasibility, and 1-year oncologic results for patients with IR-PCa treated with TPFLA in an office setting. Materials and Methods: NCT05241236 aimed to evaluate TPFLA for the International Society of Urological Pathology-grade 2 (ISUP-2) tumors. All procedures were performed in the office using MR/US fusion imaging. The diode interstitial laser system fibers were applied through the perineum using local anesthesia. The primary outcome was safety and tolerability. Pain scores were recorded using analog scales. Thirty-day adverse events and 1-year prostate biopsy oncologic outcomes were noted. Functional outcomes at 3 months and 1 year were compared with baseline as well. Results: Thirty patients accrued had TPFLA safely in the office with no complications. TPFLA median pain score was 1. At 30 days, one man required a transurethral resection of the prostate (TURP). There were no imaging demonstrable cancers at 3 months and a significant improvement in urinary function (p = 0.001) was noted and sustained for the year. No patient experienced urinary incontinence. No changes in sexual function were observed (p = 0.7). At 1 year, 25/30 (83%) had no clinically significant cancer. However, 14 had PCa, in 5 (17%) solely in treated areas, all ISUP-1. Seven had PCa outside the treated areas. Two had infield and outfield recurrences, both were ISUP 2. At study closure, 16 patients were free from PCa, 3 were on active surveillance, 9 were treated focally with cryoablation, and 2 were converted to radical surgical procedure. Conclusions: TPFLA appears to be a safe and an effective focal therapy for IR-PCa, offering a potential alternative to more radical treatments with a minimal periprocedural impact. Longer follow-up and larger studies are needed to confirm these results.